Research

Macro partitioning

Sarcopenic obesity (high BMI with low lean body mass) is associated with increased risk of dose-limiting chemotherapy toxicity and adverse survival outcomes in esophageal cancer patients.

For esophageal cancer patients, body composition (lean muscle mass) is as important as BMI. Doctors should consider lean body mass-based dosing for chemotherapy to reduce toxicity, especially in patients with sarcopenic obesity.

ModerateSupportsMEDIUM confidence
one study demonstrated a 5.5-fold increased risk for dose-limiting chemotoxicity among patients with sarcopenic obesity, with no increased risk among normal-weight patients with sarcopenia
Jessie A. Elliott et al. · Frontiers in Oncology · 2021

Why this rating

Based on observational studies and one specific study cited; more research is needed.

Source

Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma

Jessie A. Elliott et al. · Frontiers in Oncology · 2021

DOI 10.3389/fonc.2021.627270

narrative_reviewCited 48×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →